Berrocal María H, Acaba Luis A, Acaba Alexandra
Berrocal and Associates, San Juan, PR, USA.
Thomas Jefferson University, Philadelphia, PA, USA.
Curr Diab Rep. 2016 Oct;16(10):99. doi: 10.1007/s11892-016-0787-6.
New modalities for the treatment of diabetic eye complications have emerged in the past decade. Nevertheless, many severe diabetic retinopathy complications can only be treated with vitreoretinal surgery. Technological advances in pars plana vitrectomy have expanded the gamut of pathologies that can be successfully treated with surgery. The most common pathologies managed surgically include vitreous opacities and traction retinal detachment. The indications, surgical objectives, adjunctive pharmacotherapy, microincisional surgical techniques, and outcomes of diabetic vitrectomy for proliferative diabetic retinopathy and diabetic tractional retinal detachment will be discussed. With the availability of new microincisional vitrectomy technology, wide angle microscope viewing systems, and pharmacologic agents, vitrectomy can improve visual acuity and achieve long-term anatomic stability in eyes with severe complications from proliferative diabetic retinopathy.
在过去十年中出现了治疗糖尿病眼部并发症的新方法。然而，许多严重的糖尿病视网膜病变并发症只能通过玻璃体视网膜手术来治疗。扁平部玻璃体切除术的技术进步扩大了可以通过手术成功治疗的病症范围。手术治疗的最常见病症包括玻璃体混浊和牵引性视网膜脱离。将讨论增殖性糖尿病视网膜病变和糖尿病牵引性视网膜脱离的糖尿病玻璃体切除术的适应症、手术目标、辅助药物治疗、微小切口手术技术和结果。随着新型微小切口玻璃体切除术技术、广角显微镜观察系统和药物制剂的出现，玻璃体切除术可以提高患有增殖性糖尿病视网膜病变严重并发症的眼睛的视力，并实现长期的解剖学稳定性。
